Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push

Bristol Myers Squibb will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify its portfolio from legacy products facing generic competition and expand its CAR T-cell immunotherapy pipeline. The acquisition includes Orbital's lead in vivo CAR T-cell candidate, OTX-201, targeting autoimmune diseases, and its RNA technology platform, positioning BMS for future growth. While analysts view the deal as a strategic fit, concerns about the logistical challenges of administering such therapies tempered enthusiasm, leading to a roughly 1% decline in Bristol Myers shares.

Analysis

Bristol Myers Squibb (BMY) announced the acquisition of privately held Orbital Therapeutics for $1.5 billion in cash, a strategic move aimed at diversifying its portfolio from legacy products facing generic competition. This acquisition expands BMY's CAR T-cell immunotherapy pipeline with Orbital's lead in vivo candidate, OTX-201, targeting autoimmune diseases, and includes access to its advanced RNA technology platform. The deal underscores BMY's commitment to securing future growth drivers beyond established blockbusters like Eliquis and Revlimid.

Despite the strategic fit, BMO Capital Markets analyst Evan Seigerman expressed skepticism, stating the deal might not fundamentally alter Bristol's narrative due to the therapeutic burden and logistical challenges associated with autoimmune cell therapies. This cautious sentiment, coupled with the fact that existing CAR T-cell therapies (Abecma, Breyanzi) constituted only 1.7% of BMY's total revenue last year, contributed to Bristol Myers shares falling approximately 1% in early trading. The overall market sentiment is mixed with a cautious tone, reflecting a moderate market impact.

Orbital's OTX-201 represents an innovative in vivo CAR T-cell approach, potentially simplifying treatment by enabling the patient's body to generate CAR-T cells, bypassing complex external engineering. Furthermore, BMY gains access to Orbital's RNA technology, which leverages AI for customizable treatments across various diseases, indicating a long-term investment in advanced therapeutic modalities. This marks BMY's first major acquisition of the year, following a smaller deal for 2seventy bio, signaling an aggressive push into next-generation therapies.

Key Decisions for Investors

• Investors should closely monitor the integration of Orbital Therapeutics and the clinical development progress of OTX-201, particularly given the analyst's concerns regarding logistical challenges in autoimmune cell therapies.
• Evaluate Bristol Myers Squibb's ability to leverage Orbital's RNA technology and AI capabilities to create new growth avenues, as current CAR T-cell products contribute minimally to overall revenue.
• Consider the long-term implications of BMY's aggressive M&A strategy for pipeline diversification versus the immediate market reaction and analyst skepticism regarding its impact on the company's core narrative.